bioAffinity Technologies, Inc.
BIAF- Exchange
- Nasdaq
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001712762
No open-market purchases or sales by bioAffinity Technologies, Inc. insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $782.5K in total; no superinvestor holds it.
Other share classesBIAFW
Q3 2023 vs. Q2 2023
How the institutions holding bioAffinity Technologies, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 7 | 10 | +3 |
| Shares | 96.7K | 119.2K | +22.5K (+23.3%) |
| Value | $177.0K | $139.7K | −$37.3K (−21.1%) |
New holders (3)
Institutions that held bioAffinity Technologies, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 20,000 | $23.3K | 0.00% |
| Qube Research & Technologies Ltd | 38 | $46 | 0.00% |
| JPMorgan Chase & Co | 7 | $9 | 0.00% |
Sold out (0)
Institutions that held bioAffinity Technologies, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
None.